Detalhe da pesquisa
1.
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Blood
; 138(19): 1843-1854, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046681
2.
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Blood Adv
; 7(15): 4089-4101, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219524
3.
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442911